A Brief Review of Pharmacotherapies for Smoking Cessation

Authors:
Cho Y. Lam From The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

Search for other papers by Cho Y. Lam in
Current site
Google Scholar
PubMed
Close
 PhD
,
Jennifer A. Minnix From The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

Search for other papers by Jennifer A. Minnix in
Current site
Google Scholar
PubMed
Close
 PhD
,
Jason D. Robinson From The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

Search for other papers by Jason D. Robinson in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Paul M. Cinciripini From The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

Search for other papers by Paul M. Cinciripini in
Current site
Google Scholar
PubMed
Close
 PhD
Full access

The U.S. Department of Health and Human Services' Clinical Practice Guidelines have established both nicotine and nonnicotine-based pharmacotherapies as efficacious treatments for smoking cessation. Smokers attempting to quit smoking can significantly increase their chances by using one of several first-line agents, including nicotine transdermal patches, gum, nasal spray, inhalers, tablets, and the antidepressant bupropion. Those who cannot use either bupropion or nicotine replacement therapy because of contraindications or lack of effectiveness may benefit from the second-line treatment nortriptyline. This article also discusses several novel compounds for smoking cessation.

Correspondence: Cho Y. Lam, PhD, Department of Behavioral Science – Unit 1330, The University of Texas M. D. Anderson Cancer Center, P. O. Box 301439, Houston, TX 77230-1439. E-mail: cholam@mdanderson.org
  • Collapse
  • Expand
  • 1.

    Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 1997–2001. MMWR Morb Mortal Wkly Rep 2005;54:625628.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    IARC Working Group on the Evaluaion of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004;83:11438.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Centers for Disease Control and Prevention. Smoking cessation during previous year among adults—United States 1990 & 1991. MMWR Morb Mortal Wkly Rep 1993;42:504507.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Fiore MC, Bailey WC, Cohen SJ et al.. Treating tobacco use and dependence. Clinical practice guideline. Rockville MD: U.S. Department of Health and Human Services, 2000.

  • 5.

    Silagy C, Lancaster T, Stead L et al.. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004;3:CD000146.

  • 6.

    Garvey AJ, Kinnunen T, Nordstrom BL et al.. Effects on nicotine gum dose by level of nicotine dependene. Nicotine Tob Res 2000;2:5363.

  • 7.

    Frishman WH, Mitta W, Kupersmith A, Ky T. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol Rev 2006;14:5773.

  • 8.

    Doherty K, Militello FS, Kinnunen T, Garvey AJ. Nicotine gum dose and weight gain after smoking cessation. J Consult Clin Psychol 1996;64:799807.

  • 9.

    Hughes JR, Hatsukami DK, Skoog KP. Physical dependence on nicotine in gum. A placebo substitution trial. JAMA 1986;255:32773279.

  • 10.

    Fiore MC, Jorenby DE, Baker TB, Kenford SL. Tobacco dependence and the nicotine patch: Clinical guidelines for effective use. JAMA 1992;368:26872694.

  • 11.

    Hajek P, West R, Foulds J et al.. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999;159:20332038.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Hughes JR, Lesmes GR, Hatsukami DK et al.. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res 1999;1:169174.

  • 13.

    Jorenby DE, Stevens SS, Fiore MC et al.. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995;274:13471352.

  • 14.

    Schneider NG, Olmstead R, Mody FV et al.. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 1995;90:16711682.

  • 15.

    Schneider NG, Olmstead R, Nilsson F et al.. Efficacy of a nicotine inhaler in smoking cessation: A double-blind, placebo-controlled trial. Addiction 1996;91:12931306.

  • 16.

    Shiffman S, Dresler CM, Hajek P et al.. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002;162:12671276.

  • 17.

    Shiffman S, Dresler CM, Rohay JM. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction 2004;99:8392.

  • 18.

    Molander L, Lunell E. Pharmacokinetic investigation of a nicotine sublingual tablet. Eur J Clin Pharmacol 2001;56:813819.

  • 19.

    Kornitzer M, Boutsen M, Dramaix M et al.. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995;24:4147.

  • 20.

    Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2000;160:128134.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Tonnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. Eur Respir J 2000;16:717722.

  • 22.

    Blondal T, Gudmundsson LJ, Olafsdottir I et al.. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. Br Med J 1999;318:285289.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Jorenby DE, Leischow SJ, Nides MA et al.. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685691.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Schuurmans MM, Diacon AH, Van Biljon X, Bolliger CT. Effects of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. Addiction 2004;99:634640.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Perkins K. Response to Dar and Frenk 2004, ``Do smokers self-administer pure nicotine? A Review of the evidence''. Psychopharmacology Berl 2004;175:256258.

  • 26.

    Johnstone EC, Yudkin PL, Hey K et al.. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004;14:8390.

  • 27.

    Yudkin P, Munafo M, Hey K et al.. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. Br Med J 2004;328:989990.

  • 28.

    Tyndale RF, Sellers EM. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther Drug Monit 2002;24:163171.

  • 29.

    Lerman C, Wileyto EP, Patterson F. The functional mu opioid receptor OPRM1. Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004;4:184192.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Fiore MC, Kenford SL, Jorenby DE et al.. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. Chest 1994;105:524533.

  • 31.

    Cepeda-Benito A. Meta-analytical review of the efficacy of nicotine chewing gum in smoking treatment programs. J Consult Clin Psychol 1993;61:822830.

  • 32.

    Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation Cochrane Review.. Cochrane Database Syst Rev 2003;4:CD000031.

  • 33.

    Ascher JA, Cole JO, Colin JN et al.. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395401.

  • 34.

    Balfour D. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens. Nicotine Tob Res 2004;6:899912.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999;288:8892.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology Berl 2003;168:347358.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Hurt RD, Sachs DPL, Glover ED et al.. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:11951202.

  • 38.

    Hays JT, Hurt RD, Rigotti NA et al.. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. Ann Intern Med 2001;135:423433.

  • 39.

    Hurt RD, Krook JE, Croghan IT et al.. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J Clin Oncol 2003;21:914920.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation: a randomized trial. Arch Intern Med 2004;164:17971803.

  • 41.

    Covey L, Glassman AH, Jiang H et al.. Will maintenance pharmacotherapy reduce relapse to smoking? Presented at the 12th Annual Meeting of the Society for Research on Nicotine and Tobacco. Orlando, February 15–18, 2006.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999;19:467489.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Hall SM, Reus VI, Munoz RF et al.. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998;55:683690.

  • 44.

    Hall SM, Humfleet GL, Reus VI et al.. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002;59:930936.

  • 45.

    Prochazka AV, Weaver MJ, Keller RT et al.. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998;158:20352039.

  • 46.

    da Costa CL, Younes RN, Lourenco MT. Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest 2002;122:403408.

  • 47.

    Hall SM, Humfleet GL, Reus VI et al.. Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry 2004;161:21002107.

  • 48.

    Prochazka AV, Kick S, Steinbrunn C et al.. Randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004;164:22292233.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: a review. Nicotine Tob Res 2005;7:491499.

  • 50.

    Cinciripini PM, Tsoh JY, Wetter DW et al.. Combined effects of venlafaxine, nicotine replacement & brief counseling on smoking cessation. Exp Clin Psychopharmacol 2005;13:282292.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Hitsman B, Pingitore R, Spring B et al.. Antidepressant pharmacotherapy helps some cigarette smokers more than others. J Consult Clin Psychol 1999;67:547554.

  • 52.

    Covey LS, Glassman AH. A meta-analysis of double-blind placebo controlled trials of clonidine for smoking cessation. Br J Addict 1991;86:991998.

  • 53.

    Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004;3:CD000058.

  • 54.

    Glassman AH, Stetner F, Walsh BT et al.. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA 1988;259:28632866.

  • 55.

    Tonstad S, Hays JT, Jorenby DE et al.. Varenicline phase III studies. Presented at the American Heart Association 2005 Scientific Sessions. Dallas, November 13–16, 2005.

  • 56.

    Gonzales DH, Rennard SI, Billing CB et al.. A pooled analysis of varenicline, an alpha 4 beta 2 nicotinic receptor partial agonist vs bupropion, and placebo for smoking cessation. Presented at the 12th Annual Meeting of the Society for Research on Nicotine and Tobacco. Orlando, February 15–18, 2006.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Cappelleri JC, Baker CL, Bushmakin AG, Reeves K. Effects of varenicline on craving and withdrawal symptoms. Presented at the 12th Annual Meeting of the Society for Research on Nicotine and Tobacco. Orlando, February 15–18, 2006.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Anthenelli RM, Dale LC. Rimonabant helps cigarette smokers stop smoking and prevents post cessation weight gain: results from the STRATUS-US trial. Final Program and Abstracts of 6th Annual Conference of the SRNT Europe, 39. Presented at the 6th Annual Conference of the SRNT Europe. Tubingen, Germany, October 6–9, 2004.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Dale LC. Efficacy of rimonabant in smoking cessation and prevention of post-cessation weight gain: the STRATUS-US trial. Obes Res 2004;12(Suppl 221-P):A59.

  • 60.

    Niaura R. Long-term maintenance of abstinence from smoking with rimonabant: results from the STRATUS-Worldwide trial. Presented at the International Conference of the American Thoracic Society. San Diego, May 20–25, 2005.

    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 376 181 11
PDF Downloads 108 24 5
EPUB Downloads 0 0 0